Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susanne Stowasser

Showing results (31-40 of 61) with videos related to

Pageof 7
Sort By:
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Respiratory Research|February 1, 2020
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trialsMichael Kreuter, Wim A Wuyts, Marlies Wijsenbeek, et al.
The Lancet. Respiratory Medicine|September 19, 2018
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ONBruno Crestani, John T Huggins, Mitchell Kaye, et al.
The European Respiratory Journal|November 17, 2018
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidoneLuca Richeldi, Sophie Fletcher, Huzaifa Adamali, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
BMJ Open Respiratory Research|September 1, 2018
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2017
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY TrialCarlo Vancheri, Michael Kreuter, Luca Richeldi, et al.
Respiratory Research|March 17, 2021
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseasesVincent Cottin, Luca Richeldi, Ivan Rosas, et al.
ERJ Open Research|July 23, 2024
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trialToby M Maher, R Gisli Jenkins, Vincent Cottin, et al.
Pageof 7

Showing results (31-40 of 61) with videos related to

Sort By:
Pageof 7
Journal of Comparative Effectiveness Research|December 20, 2022
Plain language summary: Clinical study of BI 1015550 as a potential treatment for idiopathic pulmonary fibrosisLuca Richeldi, Arata Azuma, Vincent Cottin, et al.
American Journal of Respiratory and Critical Care Medicine|June 23, 2016
Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic CriteriaGanesh Raghu, Athol U Wells, Andrew G Nicholson, et al.
Respiratory Research|February 1, 2020
Health-related quality of life and symptoms in patients with IPF treated with nintedanib: analyses of patient-reported outcomes from the INPULSIS® trialsMichael Kreuter, Wim A Wuyts, Marlies Wijsenbeek, et al.
The Lancet. Respiratory Medicine|September 19, 2018
Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ONBruno Crestani, John T Huggins, Mitchell Kaye, et al.
The European Respiratory Journal|November 17, 2018
No relevant pharmacokinetic drug-drug interaction between nintedanib and pirfenidoneLuca Richeldi, Sophie Fletcher, Huzaifa Adamali, et al.
Thorax|October 11, 2017
Long-term treatment of patients with idiopathic pulmonary fibrosis with nintedanib: results from the TOMORROW trial and its open-label extensionLuca Richeldi, Michael Kreuter, Moisés Selman, et al.
BMJ Open Respiratory Research|September 1, 2018
Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trialToby M Maher, Susanne Stowasser, Yasuhiko Nishioka, et al.
American Journal of Respiratory and Critical Care Medicine|September 12, 2017
Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY TrialCarlo Vancheri, Michael Kreuter, Luca Richeldi, et al.
Respiratory Research|March 17, 2021
Nintedanib and immunomodulatory therapies in progressive fibrosing interstitial lung diseasesVincent Cottin, Luca Richeldi, Ivan Rosas, et al.
ERJ Open Research|July 23, 2024
Circulating biomarkers and progression of idiopathic pulmonary fibrosis: data from the INMARK trialToby M Maher, R Gisli Jenkins, Vincent Cottin, et al.
Pageof 7